Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Introduction: the evolving role of bisphosphonate therapy in multiple myeloma.

Literature DB >> 10887095

Introduction: the evolving role of bisphosphonate therapy in multiple myeloma.

N Raje¹, K C Anderson.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2000 PMID： 10887095

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

Keyword Cloud
Cited

× No keyword cloud information.

6 in total

1. Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.

Authors: Ramón García-Sanz; Albert Oriol; María J Moreno; Javier de la Rubia; Angel R Payer; Miguel T Hernández; Luis Palomera; Ana I Teruel; María J Blanchard; Mercedes Gironella; Paz Ribas; Joan Bargay; Eugenia Abellá; Miquel Granell; Enrique M Ocio; Josep M Ribera; Jesús F San Miguel; María V Mateos
Journal: Haematologica Date: 2015-06-11 Impact factor: 9.941

2. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation.

Authors: Scott A Ely; Daniel M Knowles
Journal: Am J Pathol Date: 2002-04 Impact factor: 4.307

3. Prognostic significance of ¹⁸F-sodium fluoride in newly diagnosed multiple myeloma patients.

Authors: Mahdi Zirakchian Zadeh; Siavash Mehdizadeh Seraj; Brian Østergaard; Stephanie Mimms; William Y Raynor; Mahmoud Aly; Austin J Borja; Leila S Arani; Oke Gerke; Thomas J Werner; Hongming Zhuang; Mona-Elisabeth Revheim; Niels Abildgaard; Poul Flemming Høilund-Carlsen; Abass Alavi
Journal: Am J Nucl Med Mol Imaging Date: 2020-08-25

Introduction: the evolving role of bisphosphonate therapy in multiple myeloma.

1. Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.

2. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation.

3. Prognostic significance of ¹⁸F-sodium fluoride in newly diagnosed multiple myeloma patients.

Review 4. Hematological Diseases and Osteoporosis.

5. Effect of pathologic fractures on survival in multiple myeloma patients: a case control study.

Review 6. Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies.

Introduction: the evolving role of bisphosphonate therapy in multiple myeloma.

1. Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.

2. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation.

3. Prognostic significance of 18F-sodium fluoride in newly diagnosed multiple myeloma patients.

Review 4. Hematological Diseases and Osteoporosis.

5. Effect of pathologic fractures on survival in multiple myeloma patients: a case control study.

Review 6. Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies.

3. Prognostic significance of ¹⁸F-sodium fluoride in newly diagnosed multiple myeloma patients.